Jeet Mahal
Chief Operating Officer at JASPER THERAPEUTICS, INC.
Net worth: 529 691 $ as of 29/04/2024
Jeet Mahal active positions
| Companies | Position | Start | End |
|---|---|---|---|
| JASPER THERAPEUTICS, INC. | Chief Operating Officer | 20/03/2022 | - |
| Investor Relations Contact | 30/11/2019 | - | |
| Director of Finance/CFO | 30/11/2019 | 24/09/2023 | |
| Corporate Secretary | 30/11/2019 | - |
Career history of Jeet Mahal
Former positions of Jeet Mahal
| Companies | Position | Start | End |
|---|---|---|---|
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 30/11/2009 | 30/11/2019 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - | - |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Corporate Officer/Principal | - | - |
Training of Jeet Mahal
| University of California, Berkeley | Undergraduate Degree |
| Illinois Institute of Technology | Graduate Degree |
| North Carolina State University | Graduate Degree |
| The Fuqua School of Business | Masters Business Admin |
| Duke University | Masters Business Admin |
Statistics
International
| United States | 11 |
Operational
| Corporate Officer/Principal | 4 |
| Graduate Degree | 2 |
| Masters Business Admin | 2 |
Sectoral
| Consumer Services | 6 |
| Health Technology | 5 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| JASPER THERAPEUTICS, INC. | Finance |
| JOHNSON & JOHNSON | Health Technology |
| Private companies | 3 |
|---|---|
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
- Stock Market
- Insiders
- Jeet Mahal
- Experience
